A Phase 1b, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Camidanlumab Tesirine (ADCT-301) as Monotherapy or in Combination in Patients With Selected Advanced Solid Tumors
The purpose of this study is to find out if the investigational drug called ADCT-301 is safe in people with advanced cancers and what effects it has on that cancer.
Male and Female participants of 18 years of age and older.
Diagnosed with advanced or metastatic cancer
18 - 100
Healthy Volunteers Needed
Duration of Participation
How long you participate in this study depends on side effects you may have to the study drug. It also depends on how your cancer might respond to the study drug.
Knight Clinical Trials Information Line